SCHEMBL30852390

SCHEMBL30852390

CCOC(=O)C(CC(=O)c1ccccc1NC=O)NC(=O)C(CC(=O)c1ccccc1NC=O)NC(C)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
DHODH Q02127 1/20 0.39
KDM4E B2RXH2 6/20 0.38
ALDH1A1 P00352 5/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
LMNA P02545 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 3/20 0.37
CYP2C19 P33261 3/20 0.37
HSD17B10 Q99714 2/20 0.37
MAPT P10636 3/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27373206 1.00 GAA (0.39) GAADHODHKDM4EALDH1A1HPGD
SCHEMBL30852354 0.91 KDM4E (0.40) KDM4EALDH1A1HPGDSMN1; SMN2KMT2A
SCHEMBL30852329 0.88 MAPT (0.47) KDM4EALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL27372476 0.88 MAPT (0.47) KDM4EALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL30852368 0.82 HSD17B10 (0.48) KDM4EALDH1A1HPGDLMNAKMT2A
SCHEMBL27372475 0.82 HSD17B10 (0.48) KDM4EALDH1A1HPGDLMNAKMT2A
SCHEMBL3148792 0.81 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL16119404 0.80 HPGD (0.41) GAAKDM4EALDH1A1HPGDLMNA
SCHEMBL27372988 0.80 KDM4E (0.37) KDM4EALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL30852383 0.80 P2RX7 (0.44) KDM4EALDH1A1SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098007-A1 Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light SOLIOME INC (US) 2026-04-09 US disclosed
EP-4587007-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT Soliome, Inc. (US) 2025-07-23 EP disclosed
WO-2024059119-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT SOLIOME, INC. (US) 2024-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260098007-A1 Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light UGT8, UGT1A3, FUT5 GAA 713/4885DHODH 4432/4885KDM4E 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.